Archive for the ‘Treatment’ Category

1 in 3 Cancer-Free: Ivermectin Trial Stuns, but RESET-5 Aims Even Higher

https://zenodo.org/records/19455636

Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort

Authors/Creators

Nicolas Hulscher, MPH1, 2, Kelly Victory, MD2, James A. Thorp, MD2, Drew Pinsky, MD2, Alejandro Diaz-Villalobos, MD2, Peter Gillooly, MSc2, Foster Coulson2, Melissa Annazone2, Chloe Radesi2, Jessica Brooks2, Peter A. McCullough, MD, MPH1, 2, Harvey Risch, MD, PhD3, 2

April 7, 2026

Description

Abstract

Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer stem cells. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol.

Methods: We analyzed a prospective observational cohort of 197 cancer patients who were prescribed ivermectin and mebendazole off-label through a telemedicine platform by licensed U.S. healthcare providers. Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. As part of a clinical program evaluation, data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) to evaluate self-reported cancer outcomes, medication adherence, and adverse events. 95% confidence intervals (CI) were calculated for primary outcome measures using the Wilson score method. Dose-stratified analyses for outcomes and safety were conducted using Chi-square statistics.

Results: The cohort represented a diverse clinical profile of cancer patients, with mean age of 67 years and nearly balanced sex distribution (52.3% male, 47.7% female). Cancer types included prostate (27.9%), breast (18.3%), lung (8.6%), colon (5.1%), urologic (4.6%), pancreatic (3.0%), liver (2.5%), gynecologic (2.5%), and hematologic (2.5%) malignancies. At enrollment, participants had a median duration since initial diagnosis of 1.2 years, with 37.1% experiencing active disease progression. At 6-month follow-up, medication adherence was high with 86.9% of participants completing the full initial 90-capsule ivermectin-mebendazole prescription and 66.4% remaining on the protocol at 6 months. The Clinical Benefit Ratio (CBR) was 84.4% (95% CI: 77.0–89.8%). Notably, 48.4% (95% CI: 39.7–57.1%) of the cohort reported the strongest positive outcomes, consisting of regression (15.6%; 95% CI: 10.2–23.0%) or no current evidence of disease (NED, 32.8%; 95% CI: 25.1–41.5%). Disease stability was reported to be maintained in 36.1% (95% CI: 28.1–44.9%) of participants, while 15.6% (95% CI: 10.2–23.0%) reported disease progression. While 25.4% reported mild side effects (primarily gastrointestinal), 93.6% of those affected continued treatment through minor dose adjustments. Some participants reported concurrent conventional therapies, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%), as well as adjunctive interventions such as supplement use (49.2%), dietary modification (37.7%), and other integrative approaches.

Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumor regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, given the observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials are warranted to validate these observations and further define optimal dosing strategies. (Go to link for full-length study)

_____________

**Comment**

http://

Could These Overlooked Drugs Be a Cancer Game-Changer?

Dr. Ken Stoller, April 12, 2026

For a wonderful breakdown of the study:  https://justusrhope.substack.com/p/1-in-3-cancer-free-ivermectin-trial?  Excerpt:

Dosages and Concurrent Therapies

Patients were prescribed the medications off-label through a telemedicine platform. They received compounded oral capsules containing:

  • 25 mg of Ivermectin
  • 250 mg of Mebendazole

The study noted that these were not strictly monotherapies. Many patients were undergoing concurrent conventional treatments, including chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%). Additionally, many used adjunctive interventions such as supplements (49.2%) and dietary modifications (37.7%).

Study Completion and Attrition

Of the initial 197 patients, 75 patients failed to complete the study (meaning they did not complete the 6-month follow-up survey).

  • A total of 122 participants completed the 6-month follow-up survey, resulting in a 61.9% response rate.
  • Among the 122 who responded, adherence was high: 86.9% completed the full initial 90-capsule prescription, and 66.4% chose to remain on the protocol at the 6-month mark.

Clinical Outcomes and Tolerability

The authors reported an overall Clinical Benefit Ratio (CBR) of 84.4% among the 122 patients who completed the survey. The self-reported outcomes broke down as follows:

  • No Evidence of Disease (NED): 32.8%
  • Disease Stabilization: 36.1%
  • Tumor Regression: 15.6%
  • Disease Progression: 15.6%

Within the article, Justuserhope asked AI to evaluate the benefit of adding one agent at a time from the RESET-5 Protocol (Mebendazole, ivermectin, sulforaphane, metformin, and aged garlic extract) to the Hulscher et. al study.  The full RESET-5 reduces the likelihood of resistance development, enhances immune function, and depletes tumors of a critical survival tool – compensatory glutathione production.

The full RESET-5 Protocol boosts improvement even further by 30-40%.

_____________

**Comment**

For those of you studying this, 25 mg of ivermectin and 250mg of Mebendazole are considered pretty low dosages.  Many patients are taking much more than that, so the fact they are getting such great improvement with such low dosages is fairly amazing.  Lower dosages typically mean lower side-effects so this should be safe for nearly all to take.  Share with your doctor and work together to get the best fit.

For more:

Category:

Cancer, research, Treatment

A New Ivermectin/Mebendazole Cocktail for Cancer Treatment

https://justusrhope.substack.com/p/a-new-ivermectinmebendazole-cocktail?

A New Ivermectin/Mebendazole Cocktail for Cancer Treatment

Announcing the RESET-5™ Protocol
Justus R. Hope
Apr 05, 2026

Article Excerpts:

Resistance to chemotherapy and radiation is a well-documented challenge in oncology. Clinicians have increasingly reported that resistance can also emerge even when core repurposed drug metabolic cocktails are added to standard treatment regimens.

The Care Oncology Clinic’s 4-Drug COC Protocol — comprising Doxycycline, Atorvastatin, Mebendazole, and Metformin — represents a strong foundational approach to metabolic cancer therapy. In the METRICS trial, adding this protocol to standard of care in Glioblastoma was associated with nearly a one-year increase in survival.

The Problem of Resistance in Metabolic Protocols

Despite these promising results, resistance to the COC Protocol has been reported as well. The core problem lies in the nature of Cancer Stem Cells (CSCs): these cells are remarkably adaptable. When placed under primarily metabolic pressure, CSCs exploit alternative fuel sources and, given enough time, appear to reliably escape any single-axis metabolic attack.

Building a more powerful, resistance-prevention protocol requires a broader strategy — one that targets far more than cancer’s metabolism alone.

The RESET-5™ Protocol (Redox, Epigenetic, and Stem-cell Eradication Therapy)

Why it works:

The word “reset” profoundly captures what this protocol does compared to COC. While COC essentially attempts to starve the tumor, this protocol chemically resets the cancer’s mutated epigenome (via SFN), resets the gut microbiome (via AGE), and eradicates the root stem cells.

  • The RESET-5 Protocol (Mebendazole, Ivermectin, Sulforaphane, Metformin, Aged Garlic Extract) represents a significant improvement over the traditional 4-drug Care Oncology Clinic (COC) protocol (Doxycycline, Atorvastatin, Metformin, Mebendazole).
  • While the COC protocol relies on broad metabolic starvation and mitochondrial toxicity, the RESET-5 protocol systematically targets cancer stem cell (CSC) networks, reverses epigenetic mutations, and modulates the redox environment without destroying the host’s immune system or microbiome.

(See link for article and charts)

For more:

Category:

Cancer, Treatment

Review of Parasites and Their Treatments: Parasite Detox & Parasite Cleanse Guide

https://theplqn.substack.com/p/review-of-parasites-and-their-treatments?

Review of Parasites and their Treatments: Parasite Detox and Parasite Cleanse Guide

How to safely and effectively get rid of parasites
DR. ASCENSION’S HEALTH HUB
Dec 14, 2023

Disclaimer: I am a physician for 25+ years, and I’ve worked on establishing clinical practice guidelines for numerous healthcare entities (insurers and hospitals) as part of my career. Having said that, I’m not your personal physician. I believe that each person deserves personalized care based on their symptoms, test results, presence or absence of risk factors associated with parasites, diet and lifestyle, personal & family history, etc. This post is to provide you with the necessary information about 2 types of parasites: protozoa and helminths (worms). Compared to many countries who have many risk factors, including their environment and contaminated food/water supplies, the US nearly does not have the number of parasitic infections than they do. However, recent surge of illnesses, rise in inflammatory bowel disease and auto-immune disorders, association of parasites with cancers, and the fact that COVID was treatable by anti-parasitic drugs, people are reevaluating whether ‘parasites’ are a real problem in the US as well. For this reason, the information provided below, should help one evaluate their own risk so that they can determine the need for treatment and/or a cleanse, with their physician’s guidance. Please keep in mind the following:

  1. While i’ve tried to make it a thorough review, there are numerous parasites. There maybe some missing, either because they don’t infect humans, or there were no recommended treatments found for them. Feel free to add comments if I missed any that you want more information on.
  2. This review does not cover fungal infections or viral infections. Many viruses are known to cause cancers as well, such as, EBV, HPV, HCV, etc. They have their own treatment protocols.
  3. I’ve included recommended treatments based on review of multiple sources. If there is new evidence that supports the use of a drug for a parasite that I have not listed, feel free to add in comments, so I can review the study and add to the recommendations.

What are Parasites?

Parasites require a host to survive and spread. The adult forms of parasites live and feed from within the host (animals, humans). The eggs and larvae are what ‘spread’ through various means (food, water, flies, bugs and mosquitos). Most parasites, go undetected, and people are ‘asymptomatic’ because the parasite does not disturb the environment. Sometimes, there are slight symptomatic changes, but the person doesn’t think of them as worm related. For example, feeling more hungry, desiring more sweet foods, bloating or indigestion, abdominal discomfort or pain if you don’t eat, and general fatigue and malaise. These maybe signals sent by the parasite, so you take the actions that benefit them, i.e. survive, and have a constant source of food.

General To-Do’s and Not-To-Do’s about Parasites

Here are some To-Do’s:

  • Vitamin rich foods or supplements:
    • Carrots, sweet potatoes, and squash are high in beta-carotene, which turns into Vitamin A, which helps to resist parasitic worms and larvae.
    • Eat foods rich in Vitamins C & B
      • B12 is depleted by many worms
      • Folic acid (Vitamin B9) also depletes from malabsorption due to worms
  • Minerals such Selenium and Zinc: Selenium and Zinc are required for immune function and resistance to infection
  • Include more garlic in your meals: raw garlic has sulfur containing amino acids that are anti-parasitic
  • Ensure you have “good” bacteria in your gut by taking probiotics or eating probiotic rich foods like yogurt. (see below regarding probiotics used for natural treatment and prevention of parasites)
  • Perform ‘gut cleansing’, such as with psyllium, beetroot, flaxseeds or supplements containing Senna
  • Wash all foods well, including vegetables and fruits, prior to use

Here are some Not-To-Do’s:

  • Don’t eat raw or undercooked meats, fish, crustaceans, and snails
  • Avoid coming in contact with any animal feces or saliva, including from pets
  • Avoid coffee, sugar, alcohol, and refined grains

More information on natural prevention and treatments is provided later.

Anti-Parasitic Treatments

Parasites can be treated both naturally and with anti-parasitic medications. Natural herbs and supplements can help maintain an internal environment that prevents parasitic infections in the first place. Some herbs and supplements however, do directly reduce adult worms and egg count. But the effectiveness rate is not as high as anti-parasitic medications that have very targeted mechanism of action. More on natural treatments later.

You are likely to come across Ivermectin, Fenbendazole, Doxycycline and others drugs as treatments. Febendazole is a benzimidazole, and is just one of many other benzimidazoles available, such as albendazole, parbendazole, mebendazole, flubendazole, etc. It is a common practice for drug manufacturers to make different compounds under the same class of drugs, and those products are used in different markets and for different purposes such as animal vs. human use. Fenbendazole is used with animals and majority of data and studies on this drug are from animal studies. So while fenbendazole and albendazole are the same class of drugs, albendazole is a product recommended for use in humans but requires prescription, whereas fenbendazole is over the counter for animal use. What matters most is whether fenbendazole and albendazole have the same level of efficacy. Based on a review of many comparative studies, the efficacies vary based on parasite type. One was superior than the other in each study, but all were animal models. Efficacy studies on humans are available for albendazole, mebendazole, flubendazole, triclabendazole etc. Below, when discussing each parasite and treatment, you will notice that albendazole was recommended as ‘drug of choice’ for many parasites due to higher efficacy, compared to mebendazole, flubendazole and other benzimidazoles. Therefore, these drugs do not all work equally in terms of efficacy.

My review below is based on studied, recommended and approved drugs for the treatment of each parasite in humans. (See link for article)

______________

**Comment**

A wonderfully thorough article.

For more:

 

Category:

Parasites, Treatment

Tools, Hope, & Healing in Lyme Disease: Dr. Joseph Jemsek

http://

Tools, Hope & Healing in Lyme Disease with Dr. Joseph Jemsek

Mar 24, 2026
A webinar and Q&A on tools, hope and healing for those affected by Lyme disease with special guest Dr. Joseph Jemsek.
Sponsored by the National Lottery Community Fund and facilitated by Lyme Disease UK Patient Ambassador Morven-May MacCallum.
Joseph Jemsek, MD, trained as an infectious disease specialist and dedicated the first 20 years of his practice to patients with HIV/AIDS. In the early 2000s, an influx of patients from all over the United States started flooding his practice, the Jemsek Clinic, complaining of chronic symptoms of Lyme disease. This was the start of an unexpected new chapter that would change the course of Lyme disease treatment and of Dr. Jemsek’s own life. Dr. Jemsek evaluated over 15,000 cases of Lyme and other tick-borne illnesses and introduced dozens of pioneering treatment innovations.
You may sign up for Dr. Jemsek’s newsletter, Choose Life Over Lyme!, where he’ll be sharing twenty-five years of insights from his work decoding Lyme disease, at ChooseLifeOverLyme.com
You can access his guide Self-Help Tools to Manage Lyme Borreliosis Complex co-created with Lyme Disease UK here: lymediseaseuk.com/wp-content/uploads/2026/03/Self-Help-Tools-2026-.pdf
_____________
**Comment**
Highly recommend!  Dr. Jemsek is not treating patients anymore but his expertise is phenomenal.  He was also persecuted for prescribing long term antibiotics to treat chronic Lyme by the North Carolina Medical Board which restricted his medical license, but was vindicated. You won’t regret the time you spend watching this.
For more:

Category:

Lyme, research, Ticks, Treatment

Best Herbal Antibiotic Plans for Lyme, Bartonella, and Babesia

https://treatlyme.com/guide/best-herbal-antibiotics-for-lyme-bartonella-babesia/

Best Herbal Antibiotic Plans for Lyme, Bartonella, and Babesia

By Dr. Marty Ross

best-herbal-antibiotics-for-lyme-bartonella-babesia
Updated: January 24, 2025

Science Meets Buhner for Best Herbal Antibiotic Options

History Speaks

Historically, most herbal antibiotic regimens for used tick-borne infections are based on the writings and experience of master herbalist Stephen Buhner. His work is science related. However, most of the herbal antibiotics he recommends do not have actual studies showing they work in the lab or in humans for killing specific tick-borne infections. For instance, he recommends Andrographis to kill Borrelia based on science showing it kills another spirochete called Leptospirosis. And Buhner recommends Sida Acuta to address Babesia because it is used as an antimalarial, even though there is no research showing it works for Babesia.

Buhner’s writings occurred before the discovery of persister Borrelia (Lyme) and Bartonella which I describe below. So, his writings did not specifically address how to deal with these hibernation forms of germs.

Enter Science

Over the last few years, researchers are rushing to find new ways to kill the terrible Bs (Borrelia, Bartonella, and Babesia). Some of the interest in looking at herbal medicine options is the discovery of hibernating persister growth states of Borrelia and Bartonella that do not respond to classic herbal medicines or prescription regimens that target growing states of these germs. Out of this laboratory work, we now know that Buhner’s Andrographis does not work against Borrelia, but many other agents do.

In 2023 Shor and Schweig published their review of newer laboratory studies showing which herbal medicines work in the lab to kill the growing, persister, and biofilm states of Borrelia and Bartonella. This work also reveals numerous agents that can kill Babesia. Table 1. below is drawn from the Shor-Schwieg article. My table is more limited than the one published in their paper but focuses on what I have found clinically to be the most relevant herbal antibiotics.

Table 1. Herbal Antibiotic Actions

How to Interpret Table 1
  • About G P B. Borrelia and Bartonella exist in growing states, hibernation states, and biofilm communities. The growing states are also called active states. The hibernators are also called persisters or stationary states. Biofilms are mostly known as biofilms. I prefer to use the terms growing (G), persister (P) and biofilms (B) while Shor and Schweig refer to active, stationary, and biofilm states. Keep this in mind if you review their article and more extensive table.
  • About Blank. In some instances, a blank space in the table means the research did not look to see if an herbal agent actually addresses the identified problem. For instance, Zhang and colleagues showed that cinnamon, clove, and oregano oils kill Borrelia biofilms, but their research did not look at whether these herbal oils help Bartonella biofilm. Given the similarity of biofilm structures, cinnamon, clove and oregano oils may actually be good agents against Bartonella biofilms.
  • About Sida Acuta and Houttuynia. Buhner recommends Sida Acuta and Houttuynia to address Bartonella. He also recommends Sida Acuta for Babesia. These key herbal antibiotics are not included in my table or the work of Shor-Schweig because there was no research conducted looking at these agents. This does not mean they do not work, but based on science, we do not know.  (See link for article)

_____________

**Comment**

The article gives numerous treatment options for each pathogen.  We can be extremely thankful to have all of this information in an easy to find and use format which is supported by science.

For more:

Category:

Babesia, Bartonella, Herbs, Lyme, research, Treatment